|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
WHO008090181 |
003 |
DE-627 |
005 |
20230425165047.0 |
007 |
cr uuu---uuuuu |
008 |
211222s2021 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)WHO008090181
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2021-006172-16-AT
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)CoVVacBoost
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study - The CoVVacBoost Study
|b Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study - The CoVVacBoost Study
|
264 |
|
1 |
|c 2021
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 16-11-2021, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: Covid (Coronavirus disease)- 19 immunisation MedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical procedures;Therapeutic area: Body processes [G] - Immune system processes [G12]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 4
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 21. Dez.
|
773 |
1 |
8 |
|g year:2021
|g day:21
|g month:12
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-006172-16
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2021
|b 21
|c 12
|